SomaLogic Inflammation Panel I

Ordering Information:

SomaLogic Inflammation Panel I Composition:

The SOMAmer reagents in this panel target the following 16 proteins, all of which participate in inflammatory processes.

CRP sE-Selectin siCAM-1 IL-8
IP-10 MMP-1 Adiponectin MMP-7
MMP-8 MMP-9 MMP-12 MMP-13
TIMP-1 TIMP-2 TIMP-3 VEGF121

Cytokines/chemokines are represented by IL-8 and IP-10 (CXCL10), while acute phase proteins are represented by CRP (pentraxin). Matrix metalloproteinases, represented by MMP-1, -7, -8, -9, -12, and -13, effect extracellular matrix proteolysis which is essential to inflammation; they also modulate chemokine activity and gradients, and activate or inactivate cytokines by proteolytic processing. Tissue inhibitors of metalloproteinases (TIMP-1, -2, and -3) help regulate MMPs, usually by binding to MMPs and inactivating them. Circulating MMPs are often bound to TIMPs. Adiponectin, produced primarily by adipocytes, has been found to have multiple anti-inflammatory activities. The cell adhesion molecules sICAM-1 and sE-selectin both play crucial roles in the trafficking of inflammatory cells. VEGF121 is a signaling protein that promotes angiogenesis, an important part of inflammation and wound healing.
This panel can be useful in the investigation and elucidation of disease entities in which inflammation plays a central role. Particular disease categories stand out: inflammatory conditions (including auto-immune), cardiovascular diseases, metabolic conditions, infectious diseases, and cancer. Quantitative measurements for all of the panel’s proteins can be found in the published scientific literature.

Testing requirements:


Requirement Value
Patient preparation None
Specimen type Serum
Minimum volume 0.25mL
Collection container Red-top tube or SST/Tiger Top Tube
   

Sample processing requirements:

Recommended blood sample collection protocol

(Please note that serum is the required sample type for this test).

1. Check the expiration date on all of the tubes.
2. Perform the venipuncture per institutional guidelines.
3. Completely fill all tubes. If blood is being drawn for several tests (including serum- and plasma-based), fill the tubes in the following order:

  • Citrate plasma;
  • Serum: red, gold or tiger-top tubes;
  • EDTA plasma: lavender top tubes of Pearl Top PPT plasma tubes.

4. Invert the tubes 8-10 times and place upright in a rack.

General blood sample processing requirements

The proper processing of the collected samples and adherence to time constraints are critical. Samples should be processed and frozen at -80° C within two hours of collection.

Serum processing

  • Allow serum to clot for 45 minutes at room temperature prior to centrifugation.
  • Centrifuge serum tubes. Spin at 2200 x g (not RPM) for 15 minutes. Observe separation of blood cells and serum, with serum layer on top.
  • Draw off only the serum and aliquot into appropriately labeled tubes.
  • Aliquot samples immediately and then place aliquoted samples in a -80°C freezer.

Storage instructions

Samples are to remain frozen at all times.

Shipping instructions

Ship samples for overnight delivery on dry ice with a copy of the test requisition (available upon request) in the packaging. Follow all US Department of Transportation and institutional requirements for labeling and packaging for shipping clinical specimens on dry ice.

Sample rejection/limitations

Samples will be rejected if they arrive in one or more of the following conditions:

  • Thawed
  • In original sample collection tubes
  • With significant hemolysis based on visual observation of a dark red color in the sample
  • Inadequate volume

Test methodology

The assay starts with dilution of the patient serum sample into one or more dilutions. The sample dilutions are incubated with the respective SOMAmer mixes pre-immobilized onto streptavidin (SA)-coated beads. The beads are washed to remove all non-specifically associated proteins and other matrix constituents. Proteins that remain specifically bound to their cognate SOMAmer reagents are tagged using an NHS-biotin reagent. After the labeling reaction, the beads are exposed to an anionic competitor solution that prevents non-specific interactions from reforming after they are disrupted (Gold et al., 2010). Essentially pure cognate-SOMAmer complexes and unbound (free) SOMAmer reagents are released from the SA beads using ultraviolet light that cleaves the photo-cleavable linker. The photo-cleavage eluate, which contains all SOMAmer reagents (some bound to a biotin-labeled protein and some free), is separated from the beads and then incubated with a second streptavidin-coated bead that binds the biotin-labeled proteins and the biotin-labeled protein-SOMAmer complexes. The free SOMAmer reagents are then removed during subsequent washing steps. In the final elution step, protein-bound SOMAmer reagents are released from their cognate proteins using denaturing conditions. These SOMAmer reagents can then be quantified by hybridization to custom DNA microarrays. The Cyanine-3 signal from the SOMAmer reagent is detected on microarrays.

Additional information

This test was developed and its performance characteristics have been determined by SomaLogic, Inc. The test has not been cleared or approved by the U.S. Food and Drug Administration. Performance characteristics refer to the analytical performance of the test. Results should be used by the ordering physician in conjunction with other health information. The SomaLogic Clinical Laboratory is a high-complex testing facility regulated by the Clinical Laboratory Improvement Amendments (CLIA) of 1988.